PE20131101A1 - Formulaciones estables al almacenamiento de oxicodona y naloxona - Google Patents
Formulaciones estables al almacenamiento de oxicodona y naloxonaInfo
- Publication number
- PE20131101A1 PE20131101A1 PE2013000252A PE2013000252A PE20131101A1 PE 20131101 A1 PE20131101 A1 PE 20131101A1 PE 2013000252 A PE2013000252 A PE 2013000252A PE 2013000252 A PE2013000252 A PE 2013000252A PE 20131101 A1 PE20131101 A1 PE 20131101A1
- Authority
- PE
- Peru
- Prior art keywords
- oxycodone
- naloxone
- storage stable
- stable formulations
- povidone
- Prior art date
Links
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title abstract 2
- 229960002085 oxycodone Drugs 0.000 title abstract 2
- 229960004127 naloxone Drugs 0.000 title 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 229940069328 povidone Drugs 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 229920003086 cellulose ether Polymers 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA ORAL DE LIBERACION PROLONGADA QUE COMPRENDE: a) UN MATERIAL DE LIBERACION PROLONGADA TAL COMO UN ETER DE CELULOSA, UN COPOLIMERO DE BASE METACRILICA Y/O UN ALCOHOL GRASO Y b) OXICODONA Y NALOXONA O UNA SAL DE LOS MISMOS EN UNA RELACION DE 2:1 EN PESO. TAMBIEN COMPRENDE UN MATERIAL DE RELLENO TAL COMO LACTOSA MONOHIDRATO, UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO Y/O TALCO Y UN AGLUTINANTE TAL COMO HIDROXIPROPILCELULOSA, POVIDONA, CO-POVIDONA, ALMIDON, ENTRE OTROS. DICHA COMPOSICION ES ESTABLE EN ALMACENAMIENTO DURANTE PERIODOS PROLONGADOS DE TIEMPO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37334410P | 2010-08-13 | 2010-08-13 | |
| EP10172759 | 2010-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131101A1 true PE20131101A1 (es) | 2013-09-23 |
Family
ID=43382375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000252A PE20131101A1 (es) | 2010-08-13 | 2011-08-11 | Formulaciones estables al almacenamiento de oxicodona y naloxona |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20130245054A1 (es) |
| EP (2) | EP2603205B1 (es) |
| JP (1) | JP6007176B2 (es) |
| KR (1) | KR101518143B1 (es) |
| CN (1) | CN103118668B (es) |
| AR (1) | AR082688A1 (es) |
| AU (1) | AU2011288413B2 (es) |
| BR (1) | BR112013003150B1 (es) |
| CA (1) | CA2805974C (es) |
| CH (1) | CH705678B1 (es) |
| CL (1) | CL2013000444A1 (es) |
| CO (1) | CO6680640A2 (es) |
| DE (1) | DE112011102708T5 (es) |
| DK (1) | DK178702B1 (es) |
| EC (1) | ECSP13012467A (es) |
| ES (1) | ES2409069B2 (es) |
| GB (1) | GB2495676B (es) |
| MX (1) | MX355644B (es) |
| MY (1) | MY165149A (es) |
| NO (1) | NO20130366A1 (es) |
| NZ (1) | NZ606123A (es) |
| PE (1) | PE20131101A1 (es) |
| RU (1) | RU2572695C2 (es) |
| SE (1) | SE537698C2 (es) |
| SG (1) | SG187678A1 (es) |
| SI (1) | SI2603205T1 (es) |
| TW (1) | TWI469781B (es) |
| WO (1) | WO2012020097A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1685839T1 (sl) | 1997-12-22 | 2013-08-30 | Euro-Celtique S.A. | Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| KR20040098050A (ko) | 2002-04-05 | 2004-11-18 | 유로-셀띠끄 소시에떼 아노님 | 옥시코돈 및 날록손을 포함하는 약제학적 제제 |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| EP2405915B1 (en) | 2009-03-10 | 2018-10-24 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| BR112012028656A2 (pt) | 2010-05-10 | 2016-08-09 | Euro Celtique Sa | combinação de grânulos carregados ativos com ativos adicionais |
| CA2798884C (en) | 2010-05-10 | 2016-09-13 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| US20140271893A1 (en) * | 2013-03-15 | 2014-09-18 | Mcneil-Ppc, Inc. | Coated phenylephrine particles and use thereof in pharmaceutical formulations |
| NZ716267A (en) | 2013-07-23 | 2017-05-26 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| DE112014005175T5 (de) | 2013-11-13 | 2016-07-21 | Euro-Celtique S.A. | Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3229785A2 (de) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxon-monopräparat und mehrschichttablette |
| WO2018055199A1 (en) | 2016-09-26 | 2018-03-29 | Euro-Celtique S.A. | Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio |
| AU2018252153A1 (en) * | 2017-04-13 | 2019-11-07 | Jean Paul Remon | Xanthohumol-based compositions |
| CN111686094A (zh) * | 2020-07-13 | 2020-09-22 | 云南民族大学 | 一种脂肪醇类化合物在制备通便药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0164669B1 (de) | 1984-06-13 | 1991-01-23 | Röhm Gmbh | Verfahren zum Überziehen von Arzneiformen |
| EP1442745A1 (en) * | 1993-10-07 | 2004-08-04 | Euro-Celtique | Orally administrable opioid formulations having extended duration of effect |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| JP4848558B2 (ja) * | 2001-05-08 | 2011-12-28 | トーアエイヨー株式会社 | 塩酸メトホルミン含有速放性錠剤 |
| DK1416842T3 (da) * | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
| US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| JP2003160487A (ja) * | 2001-11-20 | 2003-06-03 | Ohara Yakuhin Kogyo Kk | プラバスタチンナトリウム含有錠剤およびその製造法 |
| KR20040098050A (ko) * | 2002-04-05 | 2004-11-18 | 유로-셀띠끄 소시에떼 아노님 | 옥시코돈 및 날록손을 포함하는 약제학적 제제 |
| US20060009478A1 (en) * | 2003-10-15 | 2006-01-12 | Nadav Friedmann | Methods for the treatment of back pain |
| EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
| EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
| DE102005048293A1 (de) * | 2005-10-08 | 2007-04-12 | Sanofi-Aventis Deutschland Gmbh | Retardformulierung für Pralnacasan |
| KR100753480B1 (ko) * | 2006-01-27 | 2007-08-31 | 씨제이 주식회사 | 잘토프로펜 함유 서방성 정제 및 그 제조방법 |
| US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| JP2009298707A (ja) * | 2008-06-11 | 2009-12-24 | Ohara Yakuhin Kogyo Kk | 粒子加工方法 |
| EP3045043B1 (en) * | 2009-02-26 | 2020-04-29 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
-
2011
- 2011-08-11 GB GB1301916.1A patent/GB2495676B/en active Active
- 2011-08-11 EP EP11743537.0A patent/EP2603205B1/en active Active
- 2011-08-11 BR BR112013003150-6A patent/BR112013003150B1/pt active IP Right Grant
- 2011-08-11 EP EP18197869.3A patent/EP3505162A1/en active Pending
- 2011-08-11 SG SG2013007968A patent/SG187678A1/en unknown
- 2011-08-11 PE PE2013000252A patent/PE20131101A1/es not_active Application Discontinuation
- 2011-08-11 RU RU2013110820/15A patent/RU2572695C2/ru not_active IP Right Cessation
- 2011-08-11 KR KR1020137006255A patent/KR101518143B1/ko active IP Right Grant
- 2011-08-11 MY MYPI2013000345A patent/MY165149A/en unknown
- 2011-08-11 DE DE112011102708T patent/DE112011102708T5/de not_active Withdrawn
- 2011-08-11 AU AU2011288413A patent/AU2011288413B2/en active Active
- 2011-08-11 SI SI201131634T patent/SI2603205T1/sl unknown
- 2011-08-11 MX MX2013001757A patent/MX355644B/es active IP Right Grant
- 2011-08-11 CH CH00443/13A patent/CH705678B1/de not_active IP Right Cessation
- 2011-08-11 US US13/816,685 patent/US20130245054A1/en not_active Abandoned
- 2011-08-11 WO PCT/EP2011/063864 patent/WO2012020097A2/en active Application Filing
- 2011-08-11 JP JP2013523625A patent/JP6007176B2/ja not_active Expired - Fee Related
- 2011-08-11 NZ NZ60612311A patent/NZ606123A/en not_active IP Right Cessation
- 2011-08-11 ES ES201390024A patent/ES2409069B2/es not_active Expired - Fee Related
- 2011-08-11 CA CA2805974A patent/CA2805974C/en active Active
- 2011-08-11 SE SE1350286A patent/SE537698C2/sv not_active IP Right Cessation
- 2011-08-11 CN CN201180039157.XA patent/CN103118668B/zh not_active Expired - Fee Related
- 2011-08-12 TW TW100128862A patent/TWI469781B/zh not_active IP Right Cessation
- 2011-08-15 AR ARP110102958A patent/AR082688A1/es not_active Application Discontinuation
-
2013
- 2013-02-13 CO CO13029565A patent/CO6680640A2/es not_active Application Discontinuation
- 2013-02-13 DK DKPA201370075A patent/DK178702B1/en not_active IP Right Cessation
- 2013-02-13 CL CL2013000444A patent/CL2013000444A1/es unknown
- 2013-02-28 EC ECSP13012467 patent/ECSP13012467A/es unknown
- 2013-03-12 NO NO20130366A patent/NO20130366A1/no not_active Application Discontinuation
-
2015
- 2015-12-14 US US14/968,620 patent/US20160095853A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131101A1 (es) | Formulaciones estables al almacenamiento de oxicodona y naloxona | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| CR20120443A (es) | Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| CO6440533A2 (es) | Nucleósidos espiro oxetánicos uracílicos | |
| PE20130657A1 (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
| AR084620A1 (es) | Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson | |
| AR065096A1 (es) | Preparacion solida | |
| CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
| PE20070698A1 (es) | Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol | |
| PA8842201A1 (es) | Inhibidores macrocíclicos de serina proteasas de hepatitis c | |
| AR081670A1 (es) | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| CR20130239A (es) | Compuestos de triazolopiridina | |
| UY33201A (es) | Compuestos de pirazol como antagonistas de crth2. | |
| BR112013030456A2 (pt) | composição farmacêutica compreendendo derivado de amida inibindo o crescimento de células de câncer e lubrificante de sal não-metálico | |
| ECSP11011555A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
| DOP2010000331A (es) | Formulacion de medicamento solida con liberacion retardada | |
| MX2013006420A (es) | Derivados de aminotriazol hidrolixado como agonistas del receptor de alx. | |
| IN2015DN03921A (es) | ||
| PE20131035A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| UY29365A1 (es) | Nueva forma de sal de un agonista de dopamina | |
| AR080127A1 (es) | Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |